Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice ; volume:16 ; number:1 ; day:16 ; month:2 ; year:2016 ; pages:1-9 ; date:12.2016
BMC cancer ; 16, Heft 1 (16.2.2016), 1-9, 12.2016
- Creator
-
Razenberg, L. G. E. M.
- Contributor
-
van Gestel, Y. R. B. M.
de Hingh, I. H. J. T.
Loosveld, O. J. L.
Vreugdenhil, G.
Beerepoot, L. V.
Creemers, G. J.
Lemmens, V. E. P. P.
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2158-8
- URN
-
urn:nbn:de:1111-2016072639949
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Razenberg, L. G. E. M.
- van Gestel, Y. R. B. M.
- de Hingh, I. H. J. T.
- Loosveld, O. J. L.
- Vreugdenhil, G.
- Beerepoot, L. V.
- Creemers, G. J.
- Lemmens, V. E. P. P.
- SpringerLink (Online service)
Other Objects (12)
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
CT texture analysis as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab
Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
CT texture analysis as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab
Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
CT texture analysis as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab
Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer